Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.
New research from the University of St Andrews, the University of Copenhagen and Drexel University has developed AI ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
The trial is being conducted at the Centre for Human Drug Research in Leiden, the Netherlands.
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.
A look at Amyotrophic Lateral Sclerosis (ALS), focusing on motor neuron degeneration, sporadic versus familial ...
7don MSN
New ALS treatment target identified: STAUFEN-1 protein reduction protects brain cells from death
University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...
Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...
SAVANNAH, Ga. (WSAV)– May is Amyotrophic Lateral Sclerosis (ALS) awareness month, but ALS United Georgia is urging people to get informed and support year-round. ALS United Georgia describes it as a ...
An error has occurred. Please try again. With a The Portland Press Herald subscription, you can gift 5 articles each month. It looks like you do not have any active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback